Compare PAGSEG Inc (PAGS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs BIO-TECHNE Corp — how do they compare? PAGSEG Inc trades at $10.65 (market cap $2.90B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 3.9× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.66%). Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and BIO-TECHNE Corp for 63 Days on average.
| PAGS | TECH | |
|---|---|---|
Market Cap | $2.90B | $11.37B |
Volume | 4,931,855 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $12.00 | $72.61 |
52-Week Low | $8.44 | $43.31 |
Typical Hold Time | 26 Days | 63 Days |
Enterprise Value | $11.04B | $11.40B |
Dividend Yield | 10.66% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7 and net income margin of 10.45%, supported by recent earnings beats. A dividend of $0.28 is scheduled for September 2026. Analyst consensus is bullish with a $10.70 price target, though RSI levels indicate potential overbought conditions near-term.
The outlook for PAGS is positive given its undervalued metrics and profitability, but risks include macroeconomic pressures in Brazil and elevated credit losses. Institutional interest remains strong, with recent buys from Bank of America. The stock presents a value opportunity with dividend income, though investors should monitor earnings consistency and interest rate impacts.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
